388 related articles for article (PubMed ID: 22240256)
1. Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients.
Witwer KW; Watson AK; Blankson JN; Clements JE
Retrovirology; 2012 Jan; 9():5. PubMed ID: 22240256
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA regulation and its effects on cellular transcriptome in human immunodeficiency virus-1 (HIV-1) infected individuals with distinct viral load and CD4 cell counts.
Duskova K; Nagilla P; Le HS; Iyer P; Thalamuthu A; Martinson J; Bar-Joseph Z; Buchanan W; Rinaldo C; Ayyavoo V
BMC Infect Dis; 2013 May; 13():250. PubMed ID: 23721325
[TBL] [Abstract][Full Text] [Related]
3. Differential microRNA expression profile between stimulated PBMCs from HIV-1 infected elite controllers and viremic progressors.
Egaña-Gorroño L; Escribà T; Boulanger N; Guardo AC; León A; Bargalló ME; Garcia F; Gatell JM; Plana M; Arnedo M;
PLoS One; 2014; 9(9):e106360. PubMed ID: 25225963
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Expression Pattern of 4 microRNAs and their Correlation with Cellular/viral Factors in PBMCs of Long Term Non-progressors and HIV Infected Naïve Individuals.
Jamshidi S; Bokharaei-Salim F; Nahand JS; Monavari SH; Moghoofei M; Garshasbi S; Kalantari S; Esghaei M; Mirzaei H
Curr HIV Res; 2022; 20(1):42-53. PubMed ID: 34493187
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-29 family expression and its relation to antiviral immune response and viro-immunological markers in HIV-1-infected patients.
Monteleone K; Selvaggi C; Cacciotti G; Falasca F; Mezzaroma I; D'Ettorre G; Turriziani O; Vullo V; Antonelli G; Scagnolari C
BMC Infect Dis; 2015 Feb; 15():51. PubMed ID: 25808800
[TBL] [Abstract][Full Text] [Related]
6. Alterations in Abundance and Compartmentalization of miRNAs in Blood Plasma Extracellular Vesicles and Extracellular Condensates during HIV/SIV Infection and Its Modulation by Antiretroviral Therapy (ART) and Delta-9-Tetrahydrocannabinol (Δ
Kopcho S; McDew-White M; Naushad W; Mohan M; Okeoma CM
Viruses; 2023 Feb; 15(3):. PubMed ID: 36992332
[TBL] [Abstract][Full Text] [Related]
7. Disease Progression in HIV-1-Infected Viremic Controllers.
Groves KC; Bibby DF; Clark DA; Isaksen A; Deayton JR; Anderson J; Orkin C; Stagg AJ; McKnight A
J Acquir Immune Defic Syndr; 2012 Dec; 61(4):407-16. PubMed ID: 22902723
[TBL] [Abstract][Full Text] [Related]
8. Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses.
Salgado M; Garcia-Minambres A; Dalmau J; Jiménez-Moyano E; Viciana P; Alejos B; Clotet B; Prado JG; Martinez-Picado J
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593044
[TBL] [Abstract][Full Text] [Related]
9. A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers.
Tomescu C; Liu Q; Ross BN; Yin X; Lynn K; Mounzer KC; Kostman JR; Montaner LJ
PLoS One; 2014; 9(7):e103209. PubMed ID: 25078947
[TBL] [Abstract][Full Text] [Related]
10. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.
Julg B; Pereyra F; Buzón MJ; Piechocka-Trocha A; Clark MJ; Baker BM; Lian J; Miura T; Martinez-Picado J; Addo MM; Walker BD
Clin Infect Dis; 2010 Jul; 51(2):233-8. PubMed ID: 20550452
[TBL] [Abstract][Full Text] [Related]
11. CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors.
O'Connell KA; Rabi SA; Siliciano RF; Blankson JN
Proc Natl Acad Sci U S A; 2011 Sep; 108(37):E689-98. PubMed ID: 21873218
[TBL] [Abstract][Full Text] [Related]
12. Highly divergent patterns of genetic diversity and evolution in proviral quasispecies from HIV controllers.
de Azevedo SSD; Caetano DG; Côrtes FH; Teixeira SLM; Dos Santos Silva K; Hoagland B; Grinsztejn B; Veloso VG; Morgado MG; Bello G
Retrovirology; 2017 May; 14(1):29. PubMed ID: 28464889
[TBL] [Abstract][Full Text] [Related]
13. Efficient Nef-mediated downmodulation of TCR-CD3 and CD28 is associated with high CD4+ T cell counts in viremic HIV-2 infection.
Khalid M; Yu H; Sauter D; Usmani SM; Schmokel J; Feldman J; Gruters RA; van der Ende ME; Geyer M; Rowland-Jones S; Osterhaus AD; Kirchhoff F
J Virol; 2012 May; 86(9):4906-20. PubMed ID: 22345473
[TBL] [Abstract][Full Text] [Related]
14. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
[TBL] [Abstract][Full Text] [Related]
15. HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice.
Salgado M; Swanson MD; Pohlmeyer CW; Buckheit RW; Wu J; Archin NM; Williams TM; Margolis DM; Siliciano RF; Garcia JV; Blankson JN
J Virol; 2014 Mar; 88(6):3340-52. PubMed ID: 24390323
[TBL] [Abstract][Full Text] [Related]
16. Role of HIV-1 phenotype in viral pathogenesis and its relation to viral load and CD4+ T-cell count.
Kupfer B; Kaiser R; Rockstroh JK; Matz B; Schneweis KE
J Med Virol; 1998 Nov; 56(3):259-63. PubMed ID: 9783695
[TBL] [Abstract][Full Text] [Related]
17. Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection.
Rabi SA; O'Connell KA; Nikolaeva D; Bailey JR; Jilek BL; Shen L; Page KR; Siliciano RF; Blankson JN
J Virol; 2011 Jan; 85(2):979-86. PubMed ID: 21068257
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.
Munshi SU; Panda H; Holla P; Rewari BB; Jameel S
PLoS One; 2014; 9(5):e95920. PubMed ID: 24828336
[TBL] [Abstract][Full Text] [Related]
19. Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1.
Bignami F; Pilotti E; Bertoncelli L; Ronzi P; Gulli M; Marmiroli N; Magnani G; Pinti M; Lopalco L; Mussini C; Ruotolo R; Galli M; Cossarizza A; Casoli C
Blood; 2012 Jun; 119(26):6259-67. PubMed ID: 22286198
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
